VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
LPTXLeap Therapeutics, Inc.
$0.77$65M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksLPTXP/E History

LPTX logoLeap Therapeutics, Inc. (LPTX) P/E Ratio History

Deep Value

Trading at 11.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2025–2025

Current P/E (TTM)
11.0x
-34% vs 5Y avg
5Y Avg P/E
16.6x
Median 16.6x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
TTM EPS$-0.34
Price$0.77
Earnings Yield9.10%
EPS Growth (1Y)103.8%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Leap Therapeutics, Inc. (LPTX) trades at a price-to-earnings ratio of 11.0x, with a stock price of $0.77 and trailing twelve-month earnings per share of $-0.34.

The current P/E is 34% below its 5-year average of 16.6x. Over the past five years, LPTX's P/E has ranged from a low of 16.6x to a high of 16.6x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, LPTX trades at a 50% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, LPTX trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LPTX DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

LPTX Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
11.0vs22.1
-50%
Below Sector
vs. S&P 500
11.0vs24.4
-55%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 104% EPS growth (1Y)

LPTX P/E vs Peers

Oncology Therapeutics Developers peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
TGTX logoTGTXTG Therapeutics, Inc.
$8B19.2-+1747%Best
MRK logoMRKMerck & Co., Inc.
$281B15.6Lowest0.74Best+8%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

LPTX Historical P/E Data (2025–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Dec 31 2025$1.16$0.0716.6x+0%

Average P/E for displayed period: 16.6x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

1+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

LPTX — Frequently Asked Questions

Quick answers to the most common questions about buying LPTX stock.

What is LPTX's P/E ratio?

Leap Therapeutics, Inc. (LPTX) trailing twelve-month P/E ratio is 11.0x, based on TTM diluted EPS of $-0.34. The 5-year average P/E is 16.6x and the historical range spans 16.6x to 16.6x.

Is LPTX stock overvalued or undervalued?

LPTX trades at 11.0x P/E, below its 5-year average of 16.6x. At the 0th percentile of its historical range (16.6x–16.6x), the stock is priced at a discount to its own history.

Is LPTX stock expensive?

No, LPTX is not expensive on a historical basis. The current P/E of 11.0x is below the 5-year average of 16.6x and sits at the 0th percentile of its valuation range.

What is LPTX's historical P/E range?

Over the past 5 years, LPTX's P/E ratio has ranged from 16.6x to 16.6x, with a median of 16.6x and an average of 16.6x. The current P/E of 11.0x places the stock at the 0th percentile of this range. Full historical data spans 2025–2025.

How does LPTX's P/E compare to the S&P 500?

LPTX trades at 11.0x P/E versus the S&P 500 median of 24.4x. The 55% discount to the market suggests lower growth expectations or perceived higher risk.

How does LPTX's valuation compare to Healthcare peers?

Leap Therapeutics, Inc. P/E of 11.0x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is LPTX's PEG ratio?

LPTX PEG ratio is N/A, based on a P/E of 11.0x and EPS growth of 103.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is LPTX's earnings yield?

LPTX earnings yield is 9.10%, the inverse of its 11.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

LPTX P/E Ratio History (2025–2025)

Quarterly valuation multiple from closing price and trailing EPS

Current16.6x
Period Avg16.6x
Range16.6x - 16.6x
Change+0%
1 quartersDec 31, 2025 - Dec 31, 2025